|
Getting your Trinity Audio player ready...
|
The collaboration between The Hong Kong Polytechnic University (PolyU) and its industry partner represents a significant stride in the advancement of cancer immunotherapy research and development. Through the establishment of the PolyU-Axis Therapeutics Joint Laboratory for Immunotherapy, both entities are poised to leverage cutting-edge technology to enhance cancer treatment modalities, particularly through the utilisation of T-cell receptor therapy. This collaboration underscores PolyU’s commitment to pioneering technological solutions in life sciences, with a specific emphasis on translational medicine and cell therapy for various diseases, including cancer.
The newly established clinical Current Good Manufacturing Practice (cGMP) facility at PolyU adheres to stringent regulatory standards outlined in the GMP Guide for Advanced Therapy Products (ATPs). Equipped with state-of-the-art technology, this facility provides a conducive environment for the development and production of innovative cancer immunotherapies. The utilisation of isolators for aseptic handling of human stem cells and immune cells underscores the commitment to maintaining high standards of safety and efficacy in clinical research and development.
From a technological perspective, the collaboration between PolyU and its partner represents a convergence of expertise in immunotherapy and cell therapy. With a focus on T-cell adoptive immunotherapy technology (TAEST), the partner is at the forefront of developing novel anti-tumour TCR-T therapies with enhanced specificity and affinity for a wide range of malignant solid tumours.
Leveraging PolyU’s research capabilities and funding support from the University Grants Committee, the partner aims to conduct clinical trials in Hong Kong, providing local patients with access to cutting-edge cancer treatments.
The partnership between PolyU and its industry partner extends beyond the development of T-cell therapies, encompassing the exploration and development of novel targeting biologics for cancer treatment. Through collaborative efforts, both institutions are poised to uncover new tumour-targeting mechanisms, including TCR-like antibodies, which hold immense promise for the future of cell-based cancer therapies.
PolyU’s expertise in chemical biology and drug discovery, coupled with the partner’s track record in immunotherapy research, positions the partnership as a driving force in advancing the frontiers of cancer treatment through technological innovation.
The establishment of the PolyU-Axis Therapeutics Joint Laboratory for Immunotherapy serves as a testament to the importance of interdisciplinary collaboration in driving scientific progress. By bringing together experts from academia and industry, the partnership seeks to bridge the gap between fundamental research and clinical application, accelerating the translation of scientific discoveries into tangible benefits for patients.
Through a shared commitment to excellence in research and development, PolyU and its partner are poised to make significant strides in the fight against cancer, ultimately improving outcomes for patients in Hong Kong and beyond.
Looking ahead, the collaboration between PolyU and its industry partner holds immense potential for driving innovation in cancer immunotherapy. With a focus on technological advancements, both institutions are committed to pushing the boundaries of what is possible in the treatment of cancer.
By harnessing the power of T-cell therapies and novel targeting biologics, the partnership aims to revolutionise cancer treatment paradigms, offering new hope to patients and paving the way for a future where cancer is no longer a devastating diagnosis, but a manageable condition.
